Forward-Looking Statements

This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our clients’ intellectual property. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section.

Use of Adjusted Financial Measures (Non-IFRS Measures)

We have provided adjusted net profit, adjusted net profit margin, adjusted EBITDA, adjusted EBITDA margin and adjusted diluted earnings per share for the corresponding periods, which excludes the share-based compensation expenses, listing expenses and foreign exchange gains or losses, and are not required by, or presented in accordance with, IFRS. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual and non-recurring items that we do not consider indicative of the performance of our business. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.
Agenda

01 2019 Annual Results

02 Leading Industry Trends Favoring WuXi Biologics

03 Financial Overview

04 Outlook & Catalysts

05 Appendix
250
Integrated Projects

59
New Projects

16
Late Phase Projects

US$5.10B
Total Backlog

280,000L
Capacity after 2022

5,666/2,474
Employees/Scientists

¥3,983.7M
Revenue

¥1,205.0M
Adj Net Profit

57.2%
Revenue YoY Growth

60.3%
Adj Net Profit YoY Growth

41.6%
Gross Profit Margin

30.2%
Adj Net Profit Margin

2019
Financial Highlights: Record Revenue and Earning Growth

**Revenue**
- RMB (mm): 2,534.5 (2018) to 3,983.7 (2019)
- Growth: 57.2%

**Gross Profit**
- GP Margin: 40.2% (2018) to 41.6% (2019)
- RMB: 1,017.8 (2018) to 1,658.8 (2019)
- Growth: 63.0%

**Adj EBITDA**
- Adj EBITDA Margin: 42.7% (2018) to 41.9% (2019)
- Growth: 54.3%

**Net Profit**
- NP Margin: 24.9% (2018) to 25.4% (2019)
- RMB: 630.5 (2018) to 1,010.3 (2019)
- Growth: 60.2%

**Adj Net Profit**
- Adj NP Margin: 29.7% (2018) to 30.2% (2019)
- RMB: 751.5 (2018) to 1,205.0 (2019)
- Growth: 60.3%

**Diluted EPS**
- RMB: 0.48 (2018) to 0.76 (2019)
- Growth: 58.3%
### Key Financials

#### CASH
- Bank balances, cash and cash deposit amounted to RMB 6,206 million in total as of Dec 31st, 2019
- Sufficient cash plus debt to support operations for 18+ months

#### LOAN
- Approx. RMB 1,901 million borrowings as of Dec. 31, 2019
- Maintains bank credit facilities of around RMB 1,633 million for future cash needs
- Operating cash flow of RMB 1,208 million, 58.7% increased YoY

#### CAPEX
- 2019 CAPEX of RMB 3.2 billion due to optimization of CAPEX flow
- 2020 CAPEX around RMB 4.5 billion including purchase of DP facility in Germany and approx. RMB 700 million to support vaccine project
Our Mission

To accelerate and transform pharmaceutical discovery, development and manufacturing in the fast growing field of biologics to benefit patients worldwide

Revenue from each project increases with its stages

<table>
<thead>
<tr>
<th>Biologics Development Process</th>
<th>Typical Duration</th>
<th>Typical Revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-IND</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug Discovery</td>
<td>2 Years</td>
<td>US$1.5-2.5 mm</td>
</tr>
<tr>
<td>Pre-Clinical Development</td>
<td>2 Years</td>
<td>US$4-6 mm</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Milestone fee ranges from US$ 10-100 mm Royalty fee ranges from 3% to 5%)</td>
</tr>
<tr>
<td>Post-IND</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early-Phase (Phases I &amp; II)</td>
<td>3 Years</td>
<td>US$4-6 mm</td>
</tr>
<tr>
<td>Clinical Development</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Late-Phase (Phase III)</td>
<td>3-5 Years</td>
<td>US$20-50 mm</td>
</tr>
<tr>
<td>Clinical Development</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Commercial Manufacturing</td>
<td>Annually</td>
<td>US$50-100 mm annually</td>
</tr>
</tbody>
</table>
2019 Pipeline Highlights

- “Follow-the- Molecule” strategy in full motion
- Added 59 molecules into the pipeline in 2019
- 250 in development and manufacturing
- 2 of 16 Phase III projects filed BLA in China and USA, more milestone achievements expected
- US$55.1 million milestone revenue in 2019, increasing 83.7% compared with 2018

Notes:
1. All of the project No. were compared to 2019 Q4
2. The arrows in black are the projects newly added from outside; the arrows in blue are the projects progressing from earlier stage thanks to our Follow-the-molecule strategy; the dashed arrows are terminated projects
Notes:
1. Integrated projects are defined as projects requiring services for multiple stages during biologics development process
2. Estimated CMO revenue when a biologic drug reaches its peak sales. A biologic drug typically reaches peak sales after a ramp-up period
Strong Backlog Growth Underpins Future Performance

- Total backlog surged to **US$5.1 bn** by the end of 2019, showing that the Company continues to gain more market share.

- Upcoming potential milestone fees* surged to **US$3.4 bn**, 70% YoY increased mainly driven by adding more WuXiBody™ projects, which will continue to improve margin profile.

- Service backlog was up to **US$1.7 bn** as of Dec. 31, 2019 to support further revenue growth in the future.

- Mar 2020 service backlog includes new biologics signed YTD and vaccine contract.

- “Follow-the-Molecule” strategy clearly demonstrate to work.

---

---

Disclaimer:
* The upcoming potential milestone fees take a longer term to charge at various development stages. The potential to realize these milestone fees is subject to the success rate of the projects and the project progress.
Follow-the-Molecule Wins More Trust from Existing Clients

Integrated Project’s No. per Customer

<table>
<thead>
<tr>
<th></th>
<th>Average</th>
<th>Top 10</th>
<th>Top 20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Integrated</td>
<td>1.7</td>
<td>6.0</td>
<td>3.0</td>
</tr>
</tbody>
</table>

Geographic Snapshot by Customer No.

- USA: 40.5%
- PRC: 39.9%
- Europe: 11.5%
- APAC*: 6.8%
- Others: 1.3%

• Multiple leading platforms, best execution and track record increase stickiness of biologics CDMO
• Follow-the-Molecule with proven track record improved winning rate of new project from existing clients to 80+%
• Existing clients contributed to 92% revenue vs new client 8% demonstrating effectiveness of our strategy
• Customer base further diversified with USA and PRC remaining most important markets

Note:
* APAC excludes PRC
“Follow-the-Molecule” Drives Customer Growth and Revenue Diversification

Number of Customers Serviced in Each Period

<table>
<thead>
<tr>
<th>Year</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count</td>
<td>78</td>
<td>124</td>
<td>163</td>
<td>202</td>
<td>220</td>
<td>266</td>
</tr>
</tbody>
</table>

CAGR: +27.8%

Average Revenue per Customer among the Top 10 Customers in Each Period (RMB mm)

<table>
<thead>
<tr>
<th>Year</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average Revenue</td>
<td>21.6</td>
<td>42.5</td>
<td>65.9</td>
<td>88.4</td>
<td>119.3</td>
<td>197.6</td>
</tr>
</tbody>
</table>

CAGR: +56.2%

Revenue % of the Top 20 and the Top 10 Customers

<table>
<thead>
<tr>
<th>Year</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Top 20 vs. Rev</td>
<td>85.4%</td>
<td>90.9%</td>
<td>80.0%</td>
<td>70.9%</td>
<td>64.6%</td>
<td>65.3%</td>
</tr>
<tr>
<td>Top 10 vs. Rev</td>
<td>65.1%</td>
<td>76.3%</td>
<td>66.7%</td>
<td>54.6%</td>
<td>47.1%</td>
<td>49.6%</td>
</tr>
</tbody>
</table>

Average Revenue per Project (RMB mm)

<table>
<thead>
<tr>
<th>Year</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average Revenue</td>
<td>9.6</td>
<td>10.1</td>
<td>12.4</td>
<td>15.9</td>
</tr>
</tbody>
</table>

The substantial increase of Average Revenue per Customer (Top 10) & Average Revenue per Project showcases our pipeline is promptly progressing to late stage and more milestone payment received.

Note:
1. Number of customers refer to those who incurred revenue during the reporting period.
CDMO Model Further Validated as Post-IND Rev. Soaring “Follow-the-Molecule” in Full-Play: Less Reliance on a Single Project

Pre-IND
CAGR: 45.5%

Post-IND
CAGR: 109.1%

Total Revenue
CAGR: 64.4%

80%+ revenue growth in late phase and commercial projects

(Pre-IND Services)
Post-IND (Early Phase Services)
Post-IND (Late Phase and Commercial Services)

14-19 Revenue CAGR: +64.4%

2014
331.9
16.4%
54.4

2015
557.0
16.4%
222.3

2016
989.0
39.9%
334.7

2017
1,618.8
31.1%
681.3

2018
2,534.5
35.2%
1,049.2

2019
3,983.7
57.2%
1,451.5

Late+ Commercial Growth: +83.1%

Pre-IND CAGR: 45.5%
Post-IND CAGR: 109.1%
Total Revenue CAGR: 64.4%

Revenue growth in late phase and commercial projects 80%+
Global Dual Sourcing within WuXi Bio: Robust Supply Chain

- World-class capabilities, expanding capacities, excellent track record and superb execution securing more projects globally than other players
- Biologics projects are sticky, securing early stage projects to ensure high likelihood of continuing to commercialization – “Follow-the-Molecule”
- Our “on-demand global capacity planning” and “global dual sourcing within WuXi Bio” fulfill our global customers’ rapid growing demand
- “Follow-the-Molecule” strategy taking on effect: more integrated projects moving to CMO stage starting from 2020
- Two Programs from DNA to BLA achieved
Global Network Ensures Success of “Follow-the-Molecule”

Providing more than 280,000 L of total bioreactor capacity and a global robust supply chain network across 5 countries.
Rapid Business Progress across Geographic Markets

- Multiple leading technology platforms to enable global innovators in three major markets, all achieved sustained high growth
- **North America (NA)** remains the most important market, up around **66.5%** in 2019
- **43.6%** growth in China, driven by favorable policies and the boost of investment in innovative drugs
- **EU** market sustained over **160.4%** CAGR growth in the past 5 years. More innovative capabilities invested to enable biotech innovation in EU. Largest client groups from Switzerland, UK and Germany
WuXi Bio: Global Top 3 and the Dominant Leader in China

Market Share of Global Biologics* Outsourcing Market by Revenue in 2019 (1)

- Lonza: 7.1%
- BI Biologics: 6.7%
- WuXi Biologics: 5.1%
- Catalent: 4.6%
- Samsung Biologics: 3.2%
- AGC Biologics: 2.3%
- Thermo Fisher Scientific: 1.6%
- Others: 69.4%

Market Share of China Biologics* Outsourcing Market by Revenue in 2019 (1)

- MabPlex: 78.6%
- BI Biopharmaceuticals: 14.5%
- GenScript: 10.9%
- Others: 5.4%

Novel mAb Discovery
- Lonza
- Boehringer Ingelheim
- Thermo Fisher
- Catalent
- AGC Biologics
- Samsung Biologics

Discovery Biology/Drug Screening
- Lonza
- Boehringer Ingelheim
- Thermo Fisher
- Catalent
- AGC Biologics
- Samsung Biologics

Cell Line Engineering/Construction
- Lonza
- Boehringer Ingelheim
- Thermo Fisher
- Catalent
- AGC Biologics
- Samsung Biologics

Bio-analytical Testing
- Lonza
- Boehringer Ingelheim
- Thermo Fisher
- Catalent
- AGC Biologics
- Samsung Biologics

Research Manufacturing
- Lonza
- Boehringer Ingelheim
- Thermo Fisher
- Catalent
- AGC Biologics
- Samsung Biologics

Assay/Formulation/Process Development
- Lonza
- Boehringer Ingelheim
- Thermo Fisher
- Catalent
- AGC Biologics
- Samsung Biologics

Cell Banking/Cell Line Characterization
- Lonza
- Boehringer Ingelheim
- Thermo Fisher
- Catalent
- AGC Biologics
- Samsung Biologics

Viral Clearance Validation
- Lonza
- Boehringer Ingelheim
- Thermo Fisher
- Catalent
- AGC Biologics
- Samsung Biologics

cGMP Manufacturing
- Lonza
- Boehringer Ingelheim
- Thermo Fisher
- Catalent
- AGC Biologics
- Samsung Biologics

Lot Release/Stability Testing
- Lonza
- Boehringer Ingelheim
- Thermo Fisher
- Catalent
- AGC Biologics
- Samsung Biologics

Source:
1. Frost & Sullivan analysis “Global Pharmaceutical Healthcare Ecosystem Market Study (2018)”, company annual & quarterly financial reports, expert interviews
* Biologics exclude cell and gene therapy
Rich Pipeline across All Biologics Formats

86 First-in-class programs

One of the largest portfolios of complex proteins consisting of bispecifics, antibody drug conjugates (ADCs) and fusion proteins

More ADCs and Bispecific projects were added, in line with global biologics innovation trend

All demonstrating globally leading technical capabilities

Note:
1. Bispecific Antibody (BsAb) Included both WuXiBodyTM projects and non-WuXiBodyTM projects
Impressive Talent Growth Forms the Basis for Business Success

Employees as of Dec 2019. Expected to reach around 6,600+ by the end of 2020

Employees holding Ph.D. or equivalent

One of the largest biologics development teams

2019 Talent retention rate >90%, Key talent: ~94%

Note:
1. As of Dec. 31, 2019
Globally Recognized Technology with 39 IP Applications

1. Proprietary Universal Bispecific Antibody Platform
2. Proprietary Ultra-high Productivity Continuous Perfusion Cell Culture Platform
3. Antibody Drug Physic-chemical Structure and Biological Activity Analysis Platform
4. Antibody Drug Purification and Formulation Development Platform
5. Comprehensive ADCs Development Platform
6. WuXi Bio DAR4 Platform

14 patent applications
1 in-licensed patent

More......
Global Company Expanding in Four Countries:
~US$1 bn CAPEX outside of China

- Construction of Ireland DS facility on track, expect to be ready in 2021
- Investment of US$240 mm for vaccine facility, reshaping global vaccine CDMO industry

WuXi Bio Speed in Ireland

- New facility in King of Prussia, Pennsylvania to meet demand and increase presence in U.S. market
- Continue to expand core capabilities and capacities
- Construction to initiate in MA Q2

Prompt Response to Market Demand

- WuXi Bio’s FIRST overseas M&A deal to enhance “Global Dual Sourcing”
- Quick access to DP facility & cross-border expansion to meet robust demand in EU

M&A Accelerated Global Footprint

- State-of-the-art DP3 facility ready for ADC project ARX788 Phase III & commercialization
- One-stop ADC platform with total 28 global ADC projects (13 INDs) enabling biologics

Well-Positioned to Lead New Wave
Winning the Battle against COVID-19

1. A cross-functional Task Force led by CEO to closely monitor daily situation, implement prompt action plan and mobilize global resources to minimize impact

2. Business Continuity Plan (BCP) covering manufacturing, global supply chain, quality assurance, EHS and admin demonstrated effective

What we achieved?

- None of total 5,666 employee has been infected
- 98%+ staff resume to work, business as normal
- No milestone delays for integrated project: winning great feedbacks from clients

ENABLE global clients to work at home: improve client stickiness beyond the crisis

- Frequent communications with clients for the latest operation update
- Share coronavirus fighting best practice with clients
- More proactive approaches to offer multiple solutions for global clients
- Boost morale for all staff and improve operational efficiency to minimize project delivery impact
Impact from Global Coronavirus Outbreak: Challenges Come with Opportunities

1. Business Continuity Plan (BCP) demonstrated effective. No projects delayed. 98% staff back to work.

2. FDA pre-approval inspection originally scheduled in Q1 2020 likely be deferred to a later date in 2020, delaying commercial manufacturing revenue.

3. A surge of demand on R&D support due to our best-in-industry timeline and premier technology platforms. Currently working on 8 programs to treat COVID-19 and in discussions with 7. Significant potential revenue in H2 2020 if these therapies prove to be effective.

Impact on Clients

- Travel ban will limit introduction of new clients and client site visits. Implementing electronic tools to attract new clients. New clients only accounted for approx. 8% revenue in 2019.
- Continue to add more clients during the outbreak. See a surge on demand on clients in Mar due to outbreak in US and EU.
- Ex-china outbreak may have less impact on our main client group i.e. small and mid-size companies as outsourcing is core to their strategy.

4. Fundamentals of our business remain very strong. Follow-the-Molecule strategy proven to be superior. Despite the temporary impact of COVID-19 in 1H, full year will still witness significant growth.
Leading Industry Trends Favoring WuXi Biologics
Bispecifics May Be the Next Wave - WuXiBody™ is Right on!

Leading Edge Technology
Empower to discover best or first-in-class molecules

Out-licensed Projects for WuXiBody™

<table>
<thead>
<tr>
<th>Year</th>
<th>Customer #</th>
<th>Project #</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>2019</td>
<td>12</td>
<td>20</td>
</tr>
</tbody>
</table>

WuXiBody™ Development Progress

<table>
<thead>
<tr>
<th>Category</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>20</td>
<td>14</td>
</tr>
<tr>
<td>Drug Discovery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preclinical</td>
<td></td>
<td>6</td>
</tr>
</tbody>
</table>

- Strong adoption of WuXiBody™ technology since its launch in 2H 2018
- 6 projects moving to preclinical to demonstrate state-of-the-art technology
- 1-2 WuXiBody™ projects will be expected to file IND in 2020
ADC Drives Additional Growth

WuXi Biologics ADCs Manufacturing by 2019

- 28 Tox Batches
- 33 Phase I GMP
- 5 Phase II GMP

50+ Global Customers
13 IND Filings
1 Clinical Phase III

ADCs Development Progress

- Total: 28
- Preclinical: 15
- Phase I: 9
- Phase II: 3
- Phase III: 1

Selected Global ADCs Partners
ADC produced with conventional method, natural DAR distribution

ADC produced with WuXi Biologics’ IP for native IgG1

ADC produced with WuXi Biologics’ IP for engineered IgG1/4

mAb in clinic: Trastuzumab

Rituximab

Drug-Antibody Ratio (DAR) Greatly Affects Efficacy And Safety of ADC

Insufficient drug load leads to low efficacy (D0)

Too high drug load causes toxicity (D6, D8)

Appropriate drug load enhances safety and efficacy (D4)

Manufacture 35g/L Process for a Bispecific: State-of-the-Art

WuXiBody™ Bispecific Platform
- Universal
- 6-18 months of time-saving
- Minimal CMC issue

WuXia Cell Line
- Robust cell line with proven track record
- Enabling 60+ Integrated Projects Per Year

WuXiUP Continuous Manufacturing Platform
- 30-50g/L
- 2,000L disposable bioreactors to achieve comparable productivity as traditional SS tanks

- 17 WuXiUP projects
- Technology successfully scaled up to MFG scale, US IND targeted 2020

<table>
<thead>
<tr>
<th>WBP3438</th>
<th>Titer (g/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TFB (Traditional Fed Batch)</td>
<td>4.6 (14-day)</td>
</tr>
<tr>
<td>IPC (Intensified Perfusion Culture)</td>
<td>35.5 (22-day)</td>
</tr>
</tbody>
</table>
WuXi Bio Speed Expedites and Enables Our Partners: 12 Months!

Utilizing sophisticated technology platforms and providing integrated services for ALL the CMC activities from DNA to IND filing in the shortest timeline globally

- Faster First In Human
- Faster approval
- Reducing product development costs and save expenses

From DNA to IND (Months)

- 24
- 21
- 18
- 15
- 12
Continuing to Gain Market Share to Support Robust Growth

**Cutting Edge Technology**
- WuXiBody™ bispecific (universal, 6-18 months of time-saving, minimal CMC issue)
- ADC (greatly enhanced DAR4, dedicated MFG sites, 10+ IND filings)
- WuXia cell line (robust cell line with proven track record)
- WuXiUP continuous manufacturing platform (30-50g/L titer, 10+x)

**Best Timeline**
- IND Filing Timeline
  - Industry average: 18-24 months
  - WuXi Bio target: 15 reduced to 12 months now!
  - WuXi Bio record: 7 months, 5 months for coronavirus related projects

**Excellent Track Record**
- 100% projects delivered
- No customer transfer out
- Excellent customer satisfaction and high recognition

**Unparalleled Capacity**
- Capacity for IND enabling projects increased from 60 per year to 80+
- Late phase capacity increased from 5 BLAs to 7 per year
- One of the largest scientist team: ~2,500
- Largest capacity using single-use bioreactor: 280,000L after 2022
Financial Overview
Excellent Financial Performance

Revenue
RMB mm

Adjusted EBITDA (1)
RMB mm 29.7% 27.2% 37.6% 39.1% 42.7% 41.9%

Gross Profit
RMB mm 37.7% 34.6% 41.8% 43.3% 44.1% 45.6%

Adjusted Net Profit (2)
RMB mm 14.1% 11.7% 22.3% 26.7% 29.7% 30.2%

Notes:
1. Adjusted EBITDA represents net profit before (i) interest expenses, income tax expenses, listing expenses and (ii) certain non-cash expenses, consisting of share-based compensation, amortization and depreciation and (iii) foreign exchange (gains)/losses
2. Adjusted net profit excludes the share-based compensation expenses, Listing expenses and foreign exchange (gains)/losses
3. Refers to foreign exchange (gains)/losses
Robust Growth across All Geographic Markets

North America
RMB mm

PRC
RMB mm

Europe
RMB mm

Rest of the World
RMB mm

Notes:
1. Geographic breakdown by client headquarters
2. Rest of the world primarily includes Israel, Japan, India, South Korea
Gross Margin Snapshot

Cost of Services as % of Revenue

<table>
<thead>
<tr>
<th>Year</th>
<th>Adj. GM (%)</th>
<th>GM (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>37.7%</td>
<td>37.1%</td>
</tr>
<tr>
<td>2015</td>
<td>34.6%</td>
<td>32.4%</td>
</tr>
<tr>
<td>2016</td>
<td>41.8%</td>
<td>39.3%</td>
</tr>
<tr>
<td>2017</td>
<td>43.3%</td>
<td>40.8%</td>
</tr>
<tr>
<td>2018</td>
<td>44.1%</td>
<td>40.2%</td>
</tr>
<tr>
<td>2019</td>
<td>45.6%</td>
<td>41.6%</td>
</tr>
</tbody>
</table>

Note:
1. Adjusted gross margin excludes the share-based compensation expenses
Multiple Engines Support Sustainable High Growth

2019
WuXiBody™
Bispecifics
(Target 10-20 projects every year)

2020
Attract more CMO projects. Promote ADC integrated capabilities

2021
Royalties can be expected

2022
Vaccine CDMO Business
(Significant revenue in 2022 and beyond)
Conclusion: Business Momentum Remains Strong

In 2020, we will enable our global partners to work at home, enlarge more collaborations with our improved timeline and increased capacities, improve efficiency of our operations and continue to accelerate global footprint to achieve outstanding performance.

Gain market share and add 50+ new integrated projects vs 40 targeted in 2017-2019.

Accelerate global expansion in U.S., Ireland, and Germany to mitigate geopolitical risks and be closer to our customers.

Win more late phase projects to boost revenue growth.

Continue to invest in next-generation technologies to deliver sustainable high growth.

Significantly improve internal efficiency and be more competitive in global market.

In 2020, we will enable our global partners to work at home, enlarge more collaborations with our improved timeline and increased capacities, improve efficiency of our operations and continue to accelerate global footprint to achieve outstanding performance.

Gain market share and add 50+ new integrated projects vs 40 targeted in 2017-2019.

Accelerate global expansion in U.S., Ireland, and Germany to mitigate geopolitical risks and be closer to our customers.

Win more late phase projects to boost revenue growth.

Continue to invest in next-generation technologies to deliver sustainable high growth.

Significantly improve internal efficiency and be more competitive in global market.
2020 Key Milestones and Catalysts

- **Q2**
  - 1st IND of WuXiBody™
  - Vaccine facility dedication

- **Q3**
  - FDA pre-license inspection

- **Q4**
  - 2nd US BLA approval
  - 1st Chinese BLA approval
  - Another BLA filing in China
  - DP7 in Germany
05 Appendix
A. Financial Summary
## 2019 Financial Summary

<table>
<thead>
<tr>
<th>(RMB million)</th>
<th>2019</th>
<th>2018</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>3,983.7</td>
<td>2,534.5</td>
<td>57.2%</td>
</tr>
<tr>
<td>Cost of services</td>
<td>(2,324.9)</td>
<td>(1,516.7)</td>
<td></td>
</tr>
<tr>
<td>Gross Profit</td>
<td>1,658.8</td>
<td>1,017.8</td>
<td>63.0%</td>
</tr>
<tr>
<td>Other income</td>
<td>179.9</td>
<td>194.2</td>
<td></td>
</tr>
<tr>
<td>Impairment losses, net of reversal</td>
<td>(6.8)</td>
<td>(55.9)</td>
<td></td>
</tr>
<tr>
<td>Other gains and losses</td>
<td>21.5</td>
<td>21.1</td>
<td></td>
</tr>
<tr>
<td>Selling and marketing expenses</td>
<td>(77.1)</td>
<td>(42.4)</td>
<td></td>
</tr>
<tr>
<td>Administrative expenses</td>
<td>(367.3)</td>
<td>(227.7)</td>
<td></td>
</tr>
<tr>
<td>Research and development expenses</td>
<td>(259.7)</td>
<td>(169.3)</td>
<td></td>
</tr>
<tr>
<td>Share of loss of an associate</td>
<td>(3.1)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Financial costs</td>
<td>(19.6)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Profit before Tax</td>
<td>1,126.6</td>
<td>737.7</td>
<td>52.7%</td>
</tr>
<tr>
<td>Income tax expenses</td>
<td>(116.3)</td>
<td>(107.3)</td>
<td></td>
</tr>
<tr>
<td>Profit for the Year</td>
<td>1,010.3</td>
<td>630.5</td>
<td>60.2%</td>
</tr>
<tr>
<td>Earnings per share – Basic (RMB)</td>
<td>0.82</td>
<td>0.52</td>
<td></td>
</tr>
<tr>
<td>Earnings per share – Diluted (RMB)</td>
<td>0.76</td>
<td>0.48</td>
<td></td>
</tr>
</tbody>
</table>

**Note:**
Results may not foot due to rounding.
### Adjusted Net Profit Reconciliation

<table>
<thead>
<tr>
<th>(RMB million)</th>
<th>2019</th>
<th>2018</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net Profit</td>
<td>1,010.3</td>
<td>630.5</td>
<td></td>
</tr>
<tr>
<td>Share-based Compensation</td>
<td>202.7</td>
<td>128.3</td>
<td></td>
</tr>
<tr>
<td>Foreign Exchange Loss/(Gain)</td>
<td>(8.1)</td>
<td>(7.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Adjusted Net Profit</strong></td>
<td><strong>1,205.0</strong></td>
<td><strong>751.5</strong></td>
<td><strong>60.3%</strong></td>
</tr>
</tbody>
</table>

### Adjusted EBITDA Reconciliation

<table>
<thead>
<tr>
<th>(RMB million)</th>
<th>2019</th>
<th>2018</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>EBITDA</td>
<td>1,476.4</td>
<td>962.1</td>
<td></td>
</tr>
<tr>
<td>Share-based Compensation</td>
<td>202.7</td>
<td>128.3</td>
<td></td>
</tr>
<tr>
<td>Foreign Exchange Loss/(Gain)</td>
<td>(8.1)</td>
<td>(7.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Adjusted EBITDA</strong></td>
<td><strong>1,671.1</strong></td>
<td><strong>1,083.1</strong></td>
<td><strong>54.3%</strong></td>
</tr>
</tbody>
</table>

**Note:**
1. Results may not foot due to rounding
B. Industry Background
Global Biologics Market Overview

Biologics Represented a **US$290+ Billion Market Size in 2019**

(US$ bn)

2014-2018 CAGR: 8.0%

2018-2023E CAGR: 11.2%

**Continued to be the Fastest Growing Segment in the Pharma Industry**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Biologics</td>
<td>194.4</td>
<td>204.8</td>
<td>220.8</td>
<td>240.2</td>
<td>264.2</td>
<td>292.8</td>
<td>325.0</td>
<td>364.0</td>
<td>404.0</td>
<td>448.4</td>
</tr>
</tbody>
</table>

**Top 10 Best-selling Drugs in 2019**

(US$ bn)

- **Biologics**
  - 19.2
  - 12.1
  - 11.1
  - 10.8
  - 8.1
  - 7.5
  - 7.4
  - 7.2
  - 6.9
  - 6.9

- **Chemical**

**Biologics**

- 7.4%
- 11.0%

**Chemical**

- 4.3%
- 4.2%

**Global mAb Market Size**

(US$ bn)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>818.2</td>
<td>968.8</td>
<td>1,192.6</td>
<td>404.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>240.2</td>
<td>1,209.0</td>
<td>1,596.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CAGR

- 2014-2018: 9.5%
- 2018-2023E: 11.9%

**Global Biosimilar Market Size**

(US$ bn)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>1.7</td>
<td>2.7</td>
<td>4.3</td>
<td>5.6</td>
<td>7.7</td>
<td>11.1</td>
<td>17.4</td>
<td>28.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2022E</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>43.3</td>
</tr>
</tbody>
</table>
China Biologics Market Overview

China Biologics Market Expected to More Than Double in Size from 2018 to 2023
(RMB bn)

Higher Growth Profile in mAb and Biosimilar Than Overall Biologics in China

Supported by Unique Growth Drivers

1. Increasing Healthcare Expenditures
2. Enhanced R&D Capabilities
3. Favorable Government Policies
4. Increased Capital Investment

mAb Market

Biosimilar Market

Source: Frost & Sullivan
### Global Biologics Outsourcing Market Overview

#### This Industry Has High Entry Barriers

<table>
<thead>
<tr>
<th>1</th>
<th>High Technical Requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Fragility of macromolecules and the sensitivity of living cells that produce biologics create complex technical requirements for the discovery, development and manufacturing of biologics</td>
<td></td>
</tr>
<tr>
<td>• Need access to proprietary development platforms such as disposable bioreactors, in-house manufacturing capabilities and other novel technologies to compete effectively</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2</th>
<th>High Capital Requirements to Set Up cGMP Compliant Facilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Investment for building a new biologics manufacturing plant could be up to hundreds of millions of dollars</td>
<td></td>
</tr>
<tr>
<td>• Such a significant upfront cost, together with the lengthy process involved in biologics discovery, development and commercial manufacturing create structural funding issues for small companies and new market entrants</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3</th>
<th>Ability to Comply with the Increasingly Stringent Regulations</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Increasingly stringent regulations with regards to biologics discovery, development and commercial manufacturing, particularly cGMP manufacturing, create a high entry barrier for small biologics outsourcing services providers</td>
<td></td>
</tr>
<tr>
<td>• As China has joined ICH, a growing number of Chinese start-up biologics companies will target at the global market</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4</th>
<th>Ability to Capture Customers from Established Competitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Customers select biologics outsourcing services providers based on track record, reputation in the industry, product quality, regulatory compliance record and intellectual property protection capabilities</td>
<td></td>
</tr>
<tr>
<td>• Established biologics outsourcing services providers tend to enjoy a high customer retention rate, making it difficult for new market entrants to establish a sizable customer base</td>
<td></td>
</tr>
</tbody>
</table>

Source: Frost & Sullivan
Global Biologics Outsourcing Market Overview (Cont’d)

**Global Biologics Outsourcing Market Size**

(US$ bn)

- 2014: 5.9
- 2015: 7.2
- 2016: 8.4
- 2017: 9.9
- 2018: 11.8
- 2019: 14.3
- 2020E: 17.6
- 2021E: 22.0
- 2022E: 27.0
- 2023E: 32.4

**Multiple Drivers Supporting Tremendous Growth**

1. **Increasing R&D Spending**
   - Global Biologics R&D Spending Rate
     - 2019: 10.6%
     - 2022: 13.2%

2. **Enormous Cost and Time Saving**
   - Establishing biologics development capabilities and facilities are highly capital intensive and time consuming
   - Saves significant amount of investment and time by outsourcing

3. **Supply Chain and Capacity Mgmt.**
   - Ensure a robust supply chain and secure manufacturing capacity
   - Allow greater flexibility in managing capacity to meet demand fluctuation

4. **Leverage Outside Technology**
   - Outsourcing services provider are continuously updating technologies
   - Allow pharma and biotech companies to gain competitive edge and to focus on their core capabilities

**Global Market – Outsource VS Inhouse**

- 2013: Outsource 32.20% Inhouse 67.80%
- 2017: Outsource 36.50% Inhouse 63.50%
- 2022E: Outsource 45.80% Inhouse 54.20%

**Source:** Frost & Sullivan
China's Biologics Outsourcing Services Market is Projected to Grow at a Rapid Pace...

China's Biologics Outsourcing Services Market

(RMB bn)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>1.2</td>
<td>1.5</td>
<td>2.1</td>
<td>2.3</td>
<td>3.3</td>
<td>4.7</td>
<td>6.9</td>
<td>9.8</td>
<td>13.7</td>
<td>18.4</td>
</tr>
</tbody>
</table>

2014-2018 CAGR: 29.7%

2018-2023E CAGR: 40.8%

The Fastest Rate Globally

CAGR (2016 to 2021E)

- China: 34.8%
- Rest of the World: 26.7%
- Asia ex-China: 26.6%
- Europe: 17.1%
- US: 16.5%

WuXi Biologics is the Dominant Player in China

Market Share by Revenue in 2019

WuXi Biologics

CAGR (2016 to 2021E)

Key Growth Drivers

1. Rapid Development of China’s Biologics Market
   - Rapid growth in China’s biologics market requires support from strong discovery, development and manufacturing capabilities that are often not available in-house and hence need to be outsourced

2. Increased Capacity and Enhanced Capabilities in China
   - The emergence and improved capacity and capabilities of Chinese biologics outsourcing services providers have provided additional opportunities for overseas pharmaceutical and biotechnology companies

3. Favorable Government Policies
   - Chinese Government has published many regulations and policies to support the development of China’s biologics outsourcing services market
   - CDA is planning to establish green channel for foreign innovative biologics that are manufactured locally in China

WuXi Biologics is the Largest and Only Complete Solution Provider

<table>
<thead>
<tr>
<th>Company</th>
<th>Biologics Manufacturing Capacity</th>
<th>Expansion Plans</th>
<th>Discovery</th>
<th>Development</th>
<th>Manufacturing</th>
</tr>
</thead>
<tbody>
<tr>
<td>WuXi Biologics</td>
<td>54,000L</td>
<td>More capacity expansion globally</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Company A</td>
<td>300L</td>
<td>No significant expansion plan</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Company B</td>
<td>N/A</td>
<td>No significant expansion plan</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Company C</td>
<td>250L</td>
<td>No significant expansion plan</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Company D</td>
<td>9,000L</td>
<td>No significant expansion plan</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Company E</td>
<td>3,000L</td>
<td>No significant expansion plan</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Company F</td>
<td>500L</td>
<td>No significant expansion plan</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: Frost & Sullivan
Positive Outlook---Global Healthcare Fundraising in 2019

Global Biopharma Fundraising from VC/PE Remains Active

<table>
<thead>
<tr>
<th>Year</th>
<th>Total Amount Raised (US$ mm)</th>
<th>Number of Rounds</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>3,673</td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td>3,626</td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td>4,108</td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td>4,537</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>10,237</td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>9,415</td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>300</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>10,179</td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>16,024</td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td>14,063</td>
<td></td>
</tr>
</tbody>
</table>

China Biopharma/Biotech Raised RMB 111.6 bn in 2019

<table>
<thead>
<tr>
<th>Rounds</th>
<th>Total Amount (RMB bn)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Series A</td>
<td>308</td>
</tr>
<tr>
<td>Series B</td>
<td>38</td>
</tr>
<tr>
<td>Series C</td>
<td>63</td>
</tr>
<tr>
<td>Series D/E/F</td>
<td>24</td>
</tr>
<tr>
<td>Strategy</td>
<td>166</td>
</tr>
<tr>
<td>Seed/Angel/Others</td>
<td>158</td>
</tr>
<tr>
<td>Total</td>
<td>111.6</td>
</tr>
</tbody>
</table>

China Healthcare IPOs/Listing Raised RMB 252 bn in 2019 (RMB bn)

- Shanghai: 97.58
- HKEK: 51.78
- Shenzhen: 3.43
- NASDAQ: 99.31

Bakermckenzie: Chinese biopharma raised USD 16.5 billion with 17% increase in volume and 13% increase in value from 2018

Source:
(1) DealForma
(2) www.hsmap.com
C. WuXi Bio’s Technologies and Capabilities
### State-of-the-Art Technology Differentiates WuXi Bio

<table>
<thead>
<tr>
<th><strong>1</strong> WuXiBody™ Bispecific Platform</th>
<th><strong>2</strong> Transgenic Animal For mAbs Discovery</th>
<th><strong>3</strong> Antibody Drug Conjugate Discovery</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Combine any two antibodies and assemble into bispecifics</td>
<td>• Access to OMT’s state-of-the-art transgenic animal technology to develop fully human antibodies with high quality, specificity, expression, solubility and stability</td>
<td>• Integrate our in-house antibody discovery, toxin and linker to deliver the ideal lead ADC molecules</td>
</tr>
<tr>
<td>• Easy to express, no aggregation or mispairing, can be developed 6-18 months faster and much lower COGS than competitor platforms</td>
<td>• Proven technology platform used by 20+ other global companies</td>
<td>• Greatly simplify ADC drug development by providing a one-stop shop</td>
</tr>
<tr>
<td>• Support 50+ projects per year which attracts downstream services</td>
<td>• Support 50+ projects per year with potential downstream services</td>
<td>• 30+ ongoing projects with ADC discovery services with potential downstream services</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>4</strong> WuXia Cell Line Platform</th>
<th><strong>5</strong> Disposable Manufacturing Technology</th>
<th><strong>6</strong> WuXiUP Continuous Manufacturing Platform</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Our own proprietary cell line paired with our own proprietary algorithm is more cost-effective, more efficient and yields better results</td>
<td>• No cleaning and sterilization required for disposable bioreactors that use pre-radiated plastic bags as the production vessel in a stainless holder</td>
<td>• The next generation biologic manufacturing solution to accelerate biologics development and manufacturing as well as to improve the affordability of biologics</td>
</tr>
<tr>
<td>• License know-how generated during cell line engineering and development process to the customer in exchange for a license fee and future royalty payments</td>
<td>• A facility using disposable bioreactors can be built 12 to 18 months faster with 30% to 50% less investment, and can produce 5% to 15% more batches of products with a higher success rate compared to traditional stainless steel bioreactors</td>
<td>• 30-50g/L titer, 10+x</td>
</tr>
<tr>
<td>• Developed 270+ CHO-K1 cell lines total for therapeutic protein purpose</td>
<td></td>
<td>• Enabling 2,000L disposable bioreactors to comparable productivity as traditional SS tank through WuXiUP</td>
</tr>
</tbody>
</table>

---
Global Partners Continue to Expand

260+ global partners including 13 of the 20 largest pharmaceutical companies in the world and 26 of the 50 largest pharmaceutical companies in China
High-Impact Innovation to Enable Customers’ Success

WuXiBody™ Bispecific Platform
- Universal
- 6-18 months of time-saving
- Minimal CMC issue
- More strategic partnerships with customers

WuXia Cell Line
- Robust cell line with proven track record
- Enabling 60 Integrated Projects Per Year
- 40+ ongoing clinical projects in U.S., EU and China

WuXiUP Continuous Manufacturing Platform
- 30-50g/L titer, 10+x
- Achieving ultra-high productivity
- Enabling 2,000L disposable bioreactors to comparable productivity as 20,000L traditional SS tank

Discovery
Development
Manufacturing

Innovation of next growth cycle in biologics
**Leading Edge Technology of WuXiBody™**

**DIFFERENTIATION**
- **Universal**: almost any mAb sequence can be used to build bispecifics
- **Flexibility**: bi/tri/tetra valency based on biology

**SPEED**
Minimal CMC challenges: no expression, aggregation or purification challenges – Save 6-18 months of development time

**QUALITY**
- Expected **low immunogenicity**: natural sequence without complicated engineering
- Typical in vivo **half-life**, longer than typical bispecifics

---

More...
WuXiUP to Expedite Product Launch and Reduce Manufacturing Cost

**Comparable to Traditional bioreactors**
Enable 2,000L disposable bioreactors to achieve comparable productivity as traditional 20,000L stainless bioreactors, significantly reduce the manufacturing cost.

**High Purification Yield**
Achieve ultra-high productivity while enabling similar purification yield of the traditional purification process.

**Scale-up to GMP**
The technology is being scaled up to GMP production and will be deployed throughout our global manufacturing network.
Global Leader in Biomanufacturing Using Disposable Bioreactors

**Conventional Bioreactors**
- No cleaning and sterilization
- Simple design & operation
- Saves time and resources
- Minimal utilities
- Less maintenance and repair
- Simple qualification & validation
- Low contamination risk
- Less capital investment

**Single-Use Bioreactors**
- No stainless steel bioreactors, **14** facilities and largest users of disposables bioreactors
- **600+** batches manufactured at **98%** success rate
- Comparable COGS with **10,000L+** with **Scale-out** strategy
- **Less** CAPEX, faster in building facilities and comparable COGS
WuXi Bio Vision

“Every drug can be made and every disease can be treated” by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry.